RT Journal Article
SR Electronic
T1 New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.27.21250559
DO 10.1101/2021.01.27.21250559
A1 Sarah Esther Chang
A1 Allan Feng
A1 Wenzhao Meng
A1 Sokratis A. Apostolidis
A1 Elisabeth Mack
A1 Maja Artandi
A1 Linda Barman
A1 Kate Bennett
A1 Saborni Chakraborty
A1 Iris Chang
A1 Peggie Cheung
A1 Sharon Chinthrajah
A1 Shaurya Dhingra
A1 Evan Do
A1 Amanda Finck
A1 Andrew Gaano
A1 Reinhard Geßner
A1 Heather M. Giannini
A1 Joyce Gonzalez
A1 Sarah Greib
A1 Margrit Gündisch
A1 Alex Ren Hsu
A1 Alex Kuo
A1 Monali Manohar
A1 Rong Mao
A1 Indira Neeli
A1 Andreas Neubauer
A1 Oluwatosin Oniyide
A1 Abigail Elizabeth Powell
A1 Rajan Puri
A1 Harald Renz
A1 Jeffrey M. Schapiro
A1 Payton A Weidenbacher
A1 Rich Wittman
A1 Neera Ahuja
A1 Ho-Ryun Chung
A1 Pras Jagannathan
A1 Judith James
A1 Peter S. Kim
A1 Nuala J. Meyer
A1 Kari Nadeau
A1 Marko Radic
A1 William H. Robinson
A1 Upinder Singh
A1 Taia T. Wang
A1 E. John Wherry
A1 Chrysanthi Skevaki
A1 Eline T. Luning Prak
A1 PJ Utz
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250559.abstract
AB Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. We developed three different protein arrays to measure hallmark IgG autoantibodies associated with Connective Tissue Diseases (CTDs), Anti-Cytokine Antibodies (ACA), and anti-viral antibody responses in 147 hospitalized COVID-19 patients in three different centers. Autoantibodies were identified in approximately 50% of patients, but in <15% of healthy controls. When present, autoantibodies largely targeted autoantigens associated with rare disorders such as myositis, systemic sclerosis and CTD overlap syndromes. Anti-nuclear antibodies (ANA) were observed in ∼25% of patients. Patients with autoantibodies tended to demonstrate one or a few specificities whereas ACA were even more prevalent, and patients often had antibodies to multiple cytokines. Rare patients were identified with IgG antibodies against angiotensin converting enzyme-2 (ACE-2). A subset of autoantibodies and ACA developed de novo following SARS-CoV-2 infection while others were transient. Autoantibodies tracked with longitudinal development of IgG antibodies that recognized SARS-CoV-2 structural proteins such as S1, S2, M, N and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. COVID-19 patients with one or more autoantibodies tended to have higher levels of antibodies against SARS-CoV-2 Nonstructural Protein 1 (NSP1) and Methyltransferase (ME). We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.Competing Interest StatementC.S. received consultancy fees and research funding from Hycor Biomedical and Thermo Fisher Scientific, research funding from Mead Johnson Nutrition (MJN), and consultancy fees from Bencard Allergie. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. E.M. received consultancy fees from Roche. E.T.L.P. receives research funding from Janssen Research and Development, consultancy fees and research funding from Roche Diagnostics, is a paid consultant for Enpicom and serves on the scientific advisory board of the Antibody Society. N.J.M. reports funding to her institution from Athersys Inc, Biomarck Inc, and Quantum Leap Healthcare Collaborative, outside of the funded work. S.C. reports grants from NIAID, CoFAR, Aimmune, DBV Technologies, Astellas, Regeneron, FARE, and is an Advisory Board member for Alladapt, Genentech, Novartis, Sanofi, and received personal fees from Nutricia. All remaining authors report no conflicts of interest with the research reported in this manuscript.Funding StatementA.E.P. was supported by a Stanford Maternal and Child Health Research Institute postdoctoral fellowship. A.F. was funded by Stanford University and the Vice Provost for Undergraduate Education (VPUE) 2019-2020 Major Grant. A.N. was funded by AH 06-01 (Carreras Foundation). C.S. was funded by Universities Giessen and Marburg Lung Center and the German Center for Lung Research, University Hospital GieBen and Marburg (UKGM) research funding according to article 2, section 3 cooperation agreement, the Deutsche Forschungsgemeinschaft (DFG)-funded- SFB 1021 (C04), KFO 309 (P10) and SK 317/1-1 (Project number 428518790) as well as by the Foundation for Pathobiochemistry and Molecular Diagnostics. E.J.W. was supported by NIH grants AI105343, AI112521, AI082630, AI201085, AI123539, and AI117950 to E.J.W. E.J.W. is also supported by the Parker Institute for Cancer Immunotherapy which supports the cancer immunology program at UPenn. E.L.P. was funded by NIH UC4 DK112217 and NIH UM1-AI144288 (Autoimmunity Centers of Excellence, ACE). The ACE is a research network supported by the National Institute of Allergy and Infectious Disease (NIAID/NIH). We thank the Human Immunology Core, which assisted with COVID-19 sample processing and ELISAs, and receives infrastructure support from NIH PA30-CA016520 and NIH P30-AI0450080, and the Clinical Immunology Laboratory at the Hospital of the University of Pennsylvania. E.M. was funded by Stiftung P.E. Kempkes (06/2014, 01/2016), Deutsche Jose Carreras Leukamie-Stiftung (18R/2016), Rhon Klinikum AG (RKA No. 64). H.G. was supported by T32 HL007586. H.R. was funded by the Universities Giessen Marburg Lung Center and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC. I.N. was supported by UTHSC/UofM SARS-CoV-2/COVID-19 Research CORNET Award. K.N. was supported by NIH Grant 5U19AI057229-17, and by philanthropic support from the Sean N Parker Center COVID-19 Research Fund. M.A. was funded by the Sean N Parker Center COVID-19 Research Fund. M.R. was funded by UTHSC/UofM SARS-CoV-2/COVID-19 Research CORNET Award. N.J.M. was funded by NIH HL137006 and HL137915, which funded the enrollment, biosample collection, and clinical phenotyping of human subjects at Penn. P.J.U. was supported by National Institute of Allergy and Infectious Diseases of the National Institutes of Health, R01 AI125197-04, NIH U01 AI150741-01S1 and the Henry Gustav Floren Trust. P.S.K. was supported by the Chan Zuckerberg Biohub, and the Frank Quattrone and Denise Foderaro Family Research Fund. S.A.A. was supported by 1T32AR076951-01, Allen Institute for Immunology, and the Chen Family Research Fund. S.C. was supported by NIH grants UM2 AI130836, UM1 AI130839, and U19 AI104209. T.T.W. was supported by Chan Zuckerberg Biohub, the Searle Scholars Program, Fast Grants, the CEND COVID Catalyst Fund, and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01 AI139119, U19 AI111825, and U54 CA260517.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum or plasma samples were obtained following protocols approved by local institutional review boards (IRB) Kaiser Permanente Health Care System: IRB# 55718. Stanford Occupational Health Clinic: IRB# 55689. University of Pennsylvania: IRB # 808542. Philipps University Marburg: IRB# 57/20.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon publication of this study in a peer-reviewed journal, deidentified array data will be uploaded to the Gene Expression Omnibus (GEO) database.